Parnell CEO to present at Jefferies conference; CutisPharma names new CEO; West Pharmaceutical insider sells stock;

> Parnell Pharmaceuticals Holdings ($PARN) President and CEO, Robert Joseph, will be presenting at the Jefferies 2015 Healthcare Conference in New York next week. Release

> CutisPharma, a specialty pharmaceutical company that develops and distributes bulk drugs in kits used by pharmacists to create compounded medications, has named Neal Muni as its CEO. Release

> Karen Flynn, a West Pharmaceutical Services president, sold 3,091 shares of company stock last week at an average price of $55.24 for a total transaction of $170,746.84. Article

Suggested Articles

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

The $520 million investment includes $230 million for AZ's Dunkirk, France manufacturing site dedicated to inhalers and $275 million for R&D.

Manufacturing issues have caused GlaxoSmithKline to halt production and distribution of Excedrin, which has led to outages at some pharmacies.